MCAT: More Than a Test
As a premed, I find the role of the MCAT in shaping our future doctors both fascinating and fraught with ...
What’s Missing in Vaccine Discourse
Health policy today seems hell bent on reviving the days of yellow journalism, where sensationalization was the calling card for ...
New Year’s Resolutions Start Today!
As the New Year approaches, many individuals embark on a journey to improve their health and well-being by setting resolutions.
Abortion: Harbinger of Healthcare
We saw two major cases on abortion this week. Unfortunately, this feels like a harbinger of things to come.
Why it’s Hard to Treat a Cough
Coughs are everywhere this time of the year. They appear to be both harmless yet persistent, which make coughs particularly ...
Dark Side of Medical Research
Medical research plays a crucial role in advancing healthcare. However, the dark side of research threatens to undermine its credibility.
Financial Value of Your Diseases
CRISPR and other new technologies open doors for drug development, but which diseases get prioritized? It comes down to money ...
Time to Ditch the BMI
BMI has long been considered a standard measure of body fatness. However, it is time to reevaluate the use of ...
Dr. Rory and his Gazelle
Dr. Rory and his Gazelle is a story of patient abandonment and treatment refusal. It's sadly common for many patients ...
The Resurgence of Mobile Clinics
Mobile clinics, once a cornerstone of healthcare delivery, are experiencing a resurgence and a renewed focus on access to care.
No, Biden’s Immigration Policies are not to Blame for the Fentanyl Crisis
But this misunderstands the obvious reality about the drug: Because it is so potent, a large supply can be easily ...
SCOTUS Likely to Favor Sackler’s
As the nation grapples with the overdose epidemic, the legal battle surrounding Purdue Pharma's bankruptcy immunity has taken center stage.
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more